TH-302: Phase I/II started

Threshold began a 3-part, open-label, U.S. Phase I/II trial to evaluate IV TH-302 alone and in combination with Velcade bortezomib in up to 60 MM patients who received >=2 lines of therapy. In the first part, 6-patient cohorts will receive escalating doses of TH-302 given on days 1, 4, 8 and 11 of a 21-day cycle to determine the MTD. If >=1 patients achieve a partial response at the MTD, then enrollment will continue into the second part, which will evaluate the dose in an additional 15 patients. If data show TH-302 is well tolerated, then the trial will continue onto the third part, which will evaluate escalating doses of TH-302 in combination with Velcade. ...